Headquartered in Pasadena, CA Fiscal year ends September NASDAQ: ARWR arrowheadpharma.com
Arrowhead Pharmaceuticals is a commercial-stage pharmaceutical company that develops medicines using RNA interference (RNAi) technology to silence disease-causing genes. The company's proprietary targeted RNAi molecule (TRiM) platform enables precise gene silencing across multiple tissue types including liver, lung, muscle, adipose, and central nervous system. Its first commercialized product, REDEMPLO (plozasiran), is approved in the U.S., EU, Canada, China, and Australia for the treatment of familial chylomicronemia syndrome (FCS), a rare genetic condition causing extremely high triglyceride levels. The company is pursuing label expansion of plozasiran into severe hypertriglyceridemia based on Phase 3 SHASTA program results. Arrowhead's pipeline includes zodasiran for homozygous familial hypercholesterolemia (Phase 3), ARO-INHBE for obesity and MASH, and ARO-PNPLA3 (licensed to Madrigal Pharmaceuticals) for MASH. The company retains worldwide commercial rights to REDEMPLO outside of Greater China, where Sanofi holds the license. Updated
Iran fired on ships, Trump answered with missiles and seized the Strait of Hormuz, and Wall Street spent Tuesday sorting out who gets hurt and who benefits. Analysts at KeyBanc, HSBC, and…
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the…
Sarepta Therapeutics (NASDAQ:SRPT | SRPT Price Prediction) stock is up approximately 20% in early trading on Wednesday after the company released its first-ever clinical data from two siRNA programs targeting rare neuromuscular…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Monday's top analyst upgrades and downgrades included CyberArk Software, Diageo, Dish Network, Electronic Arts, Fox, Gilead Sciences, Molson Coors Beverage, O’Reilly Automotive, PacWest Bancorp, Palo Alto Networks, SoFi Technologies and Twilio.
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's, Microsoft, PulteGroup and Tesla.
Wednesday's top analyst upgrades and downgrades included APA, Delta Air Lines, Generac, Lululemon Athletica, Microchip Technology, Paccar, Philip Morris International, Pinduoduo, Shopify, Taboola.com and Welltower.
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor, Playtika, Peloton Interactive, Unity Software, Walmart and Wynn Resorts.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including American Water Works, Carnival, Duke Energy, Okta and Zscaler.
The Friday afternoon analyst calls were focused on Biogen, Fortinet, Pinterest, Snap and more.
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.
Chris Lange Arrowhead Pharmaceuticals is a commercial-stage pharmaceutical company that develops medicines using RNA interference (RNAi) technology to silence disease-causing genes.
The Wall Street consensus 12-month price target for ARWR is $107.23. ARWR price prediction →
